Clinical Trials Logo

Glioblastoma Multiforme clinical trials

View clinical trials related to Glioblastoma Multiforme.

Filter by:

NCT ID: NCT01808820 Completed - Clinical trials for Glioblastoma Multiforme

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

Start date: August 21, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to evaluate an investigational vaccine using patent-derived dendritic cells (DC) to treat malignant glioma or glioblastoma.

NCT ID: NCT01800695 Completed - Clinical trials for Glioblastoma Multiforme

Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme

Start date: April 2, 2013
Phase: Phase 1
Study type: Interventional

This study is evaluating the safety and pharmacokinetics of ABT-414 in subjects with glioblastoma multiforme.

NCT ID: NCT01756352 Completed - Clinical trials for Glioblastoma Multiforme

FET-PET for Evaluation of Response of Recurrent GBM to Avastin

Start date: February 2013
Phase: Phase 2
Study type: Interventional

Hypothesis: The central hypothesis underlying the proposed research study is that FET-PET will predict durable benefit in patients receiving anti-angiogenic benefit for presumed recurrent GBM (i.e. progression-free survival and overall survival). We have defined one primary specific aim, for which we expect to obtain definitive results, and two secondary aims, under which we plan to generate preliminary data to support a future, larger project.

NCT ID: NCT01631552 Completed - Clinical trials for Non-small Cell Lung Cancer

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Start date: December 17, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer. In Phase II, the primary objective is to evaluate the safety and efficacy of sacituzumab govitecan-hziy administered in 21-day treatment cycles at a dose selected in Phase I. Tumor types in the study will include: cervical, colorectal, endometrial, ovarian, esophageal, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous cell, hepatocellular, prostate, non-small-cell lung cancer, pancreatic, renal cell, small-cell lung cancer, non-triple negative breast cancer (non-TNBC), triple-negative breast cancer (TNBC) and metastatic urothelial cancer (mUC).

NCT ID: NCT01618747 Completed - Clinical trials for Glioblastoma Multiforme

An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse

Start date: March 15, 2013
Phase: N/A
Study type: Observational

This single-arm, open-label, multicenter, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse. Data will be collected from eligible patients initiated on Avastin treatment according to local label for up to 3 years.

NCT ID: NCT01588769 Completed - Clinical trials for Glioblastoma Multiforme

A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients

ALECSAT-GBM
Start date: August 2011
Phase: Phase 1
Study type: Interventional

It is the primary objective of this study to show safety and tolerability for administration of the cell based immunotherapy ALECSAT to patients with Glioblastoma brain cancer. It is a secondary objective to establish if any indications of positive therapeutic or palliative effects may be observed.

NCT ID: NCT01564914 Completed - Glioblastoma Clinical Trials

A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma

105GM201
Start date: May 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)

NCT ID: NCT01562197 Completed - Clinical trials for Glioblastoma Multiforme

A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma

AxiGII
Start date: April 2014
Phase: Phase 2
Study type: Interventional

This clinical trial will recruit patients diagnosed with glioblastoma at the time of recurrence or progression following prior treatment with surgery, radiation therapy and alkylating chemotherapy. Patients will be screened and if found eligible will be randomized to one of two treatment arms (1:1 randomization). Patients randomized to the Axitinib treatment-arm will be treated with Axitinib until progression (they can be treated after progression in the Axitinib plus lomustine arm), unacceptable treatment related toxicity, or patients refusal to continue study treatment. Patients randomized to the Axitinib plus Lomustine-arm will receive treatment until progression, unacceptable treatment related toxicity, or patients refusal to continue study treatment.

NCT ID: NCT01540513 Completed - Clinical trials for Glioblastoma Multiforme

PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404

Start date: March 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate diagnostic imaging techniques using 124I-NM404 PET/CT in human brain tumors. This goal will be accomplished by quantifying tumor uptake and determining the optimal PET/CT protocol, comparing PET tumor uptake to MRI, and calculating tumor dosimetry. The long-term goals of this research are to improve the diagnosis and treatment of malignant brain tumors by using radioiodinated NM404

NCT ID: NCT01478854 Completed - Clinical trials for Glioblastoma Multiforme

Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide

Start date: December 27, 2011
Phase: N/A
Study type: Interventional

The long term goal of this research is to establish whether NPC sparing RT techniques improve neurocognitive outcomes compared to conventional RT for brain tumors. If the proposed study demonstrates that NPC sparing RT is not associated with increased LR in the spared regions of the brain compared to conventional RT, it will ideally serve as the foundation for a future multi-institutional randomized controlled trial comparing neurocognitive outcomes in patients treated with NPC-sparing RT versus conventional radiation therapy.